The Pelthos Therapeutics Inc. (PTHS) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered tools to help interpret them. As a Nevada-incorporated biopharmaceutical company listed on the NYSE American, Pelthos files a range of documents with the U.S. Securities and Exchange Commission that describe its business, governance, and financial obligations.
Key filings include Form 8-K current reports, where Pelthos discloses material events such as financing transactions, product acquisitions, and governance changes. Recent 8-K filings describe a senior secured term loan facility with Horizon Technology Finance Corporation intended to support commercialization of ZELSUVMI and the launches of Xepi and Xeglyze, an asset purchase agreement for the Xeglyze head lice treatment, and a securities purchase agreement for senior secured convertible notes used to fund the acquisition and planned relaunch of Xepi and to accelerate ZELSUVMI commercialization.
Other 8-K items and the company’s definitive proxy statement on Schedule 14A provide detail on board composition, director compensation policies, annual meeting proposals, and shareholder voting results. These documents outline Pelthos’ governance structure, committee responsibilities, and the terms under which directors and executives are compensated and indemnified.
On Stock Titan, investors can review Pelthos’ periodic reports (such as Forms 10-K and 10-Q when filed) for information on revenue from ZELSUVMI, operating expenses, cash position, and risk factors related to its commercial dermatology portfolio and financing arrangements. Form 4 and related insider transaction reports, when available, show equity dealings by directors and officers, offering additional insight into insider alignment.
AI-driven summaries on this page highlight the most important points from lengthy filings, such as covenants in loan agreements, conversion terms in convertible notes, and implications of mergers and name changes. Real-time updates from EDGAR ensure that new Pelthos filings—whether related to financings, acquisitions, or governance—are quickly reflected, while the AI layer helps users understand how each document fits into the company’s broader strategy around ZELSUVMI, Xepi, and Xeglyze.
Pelthos Therapeutics Inc. is seeking shareholder approval at its virtual 2026 annual meeting on September 29, 2026. Holders of its 3,828,469 outstanding common shares as of August 4, 2026 may vote to elect eight directors, ratify Grant Thornton LLP as auditor for 2026, and approve the 2026 Equity Incentive Plan.
The board recommends voting FOR all director nominees and FOR Proposals 2 and 3. Significant ownership is concentrated, including Ligand Pharmaceuticals at 39.2% of common stock, with other investors each above 5%. The proxy also describes board structure, committee composition, director and executive compensation, equity award overhang under the 2023 plan, and extensive related-party and financing arrangements with Ligand and other large investors.
Pelthos Therapeutics director Ezra M. Friedberg reported small, pre-planned share sales and updated his holdings. He sold a total of 558 shares of Pelthos Therapeutics common stock in open-market transactions on July 2, 2026, including 534 shares at a weighted average price of $26.0303 and 24 shares at a weighted average price of $27.3254. According to a footnote, these sales were executed under a Rule 10b5-1 plan adopted on December 16, 2025 to satisfy estimated tax obligations from the vesting of restricted stock units granted by the company.
After these sales, Friedberg continues to hold Pelthos Therapeutics shares both directly and indirectly. Indirect holdings include 40,000 shares held by Key Recovery Group LLC and 82,072 shares held by Balmoral Financial Group LLC. Friedberg is the manager of both entities and may be deemed to beneficially own those shares but disclaims beneficial ownership except to the extent of his pecuniary interest.
Pelthos Therapeutics Inc. director Matthew Pauls reported selling 786 shares of Common Stock in open-market transactions on July 2, 2026. The sales occurred at weighted average prices of about $26 per share across multiple trades.
According to the disclosure, these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025 to help satisfy estimated tax obligations tied to the vesting of restricted stock units granted by Pelthos. After the transactions, Pauls directly held 14,364 shares of Pelthos common stock.
Pelthos Therapeutics Inc. director Peter Greenleaf reported open-market sales of a total of 797 shares of Common Stock on July 2, 2026. The trades were executed at weighted average prices of about $25.9954 and $27.2733 per share in multiple transactions.
According to the disclosure, these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025 to help satisfy estimated tax obligations tied to vesting of restricted stock units. Following the transactions, Greenleaf directly holds 23,884 shares of Pelthos Therapeutics Common Stock.
Pelthos Therapeutics Inc. director Ezra M. Friedberg reported small open-market sales of common stock alongside updated indirect holdings. On June 15, 2026, he sold 59 shares at $27.9403 per share and 224 shares at $27.1245 per share in open-market transactions.
According to a footnote, these sales were made under a pre-arranged Rule 10b5-1 plan adopted on December 16, 2025 to satisfy estimated tax obligations from vesting restricted stock units. After the sales, he held 81,600 shares directly and indirectly 40,000 shares via Key Recovery Group LLC and 82,072 shares via Balmoral Financial Group LLC.
Pelthos Therapeutics director Todd C. Davis reported open-market purchases of Pelthos common stock. On June 11, 2026, he bought a total of 35,948 shares in two transactions, at weighted average prices of $27.8046 and $28.7261 per share. Following these trades, his direct holdings increased to 75,834 common shares. The filing also shows 1,500,000 Pelthos shares held indirectly by Ligand Pharmaceuticals Incorporated, where Davis serves as Chief Executive Officer and director; he may be deemed to beneficially own these shares but disclaims beneficial ownership beyond his pecuniary interest.
Pelthos Therapeutics Inc. furnished an update as its CEO prepares to present and hold investor meetings at the Jefferies Global Healthcare Conference on June 4, 2026 in New York. The accompanying presentation highlights Pelthos as a commercial-stage biopharmaceutical company focused on cutaneous infectious diseases, led by its at-home molluscum treatment ZELSUVMI.
The deck notes that Zelsuvmi launched in July 2025 and has seen strong uptake, with more than 20,000 units dispensed from launch through April 2026, 16,774 prescribed units and 4,867 unique prescribers. As of May 11, 2026, the company lists a stock price of $26.85, approximately $240 million market capitalization and $32.0 million of cash at the end of Q1 2026.
Pelthos also emphasizes recent acquisitions of two FDA-approved dermatology products, XEPI for impetigo and XEGLYZE for head lice, with anticipated commercial launches in early 2027 and mid-2027. Management highlights overlapping prescriber call points, 64 sales territories covering about 53% of molluscum claims, and payer coverage where 70% of combined Medicaid and commercial lives are under one Zelsuvmi contract.
Pelthos Therapeutics Inc.’s Form 4 details equity changes tied to Chief Financial Officer Francis Knuettel II’s separation. A Separation Agreement dated May 15, 2026 governs forfeiture and accelerated vesting of his stock awards.
The filing reports the forfeiture and cancellation of unvested restricted stock units and stock options for no consideration, and the acceleration of vesting for 19,525 RSUs out of 33,472 previously granted under the 2023 Equity Incentive Plan. Certain stock options also became fully vested and exercisable, while others were cancelled.
Separately, the Lara Knuettel Revocable Trust, an entity associated with Mr. Knuettel, sold 1,500 shares of common stock on May 22, 2026 in open-market trades at a weighted average price of $26.8433 per share, leaving 11,316 shares held by the trust and 10,000 shares held by Camden Capital LLC.
Issuer filed a Form 144 reporting proposed affiliate sales of common stock. The notice lists 1,720 shares with an associated figure of $46,629.20 and four trade entries: 650, 550, 170, and 350 shares dated in September 2024. The broker is Fidelity Brokerage Services LLC.
Pelthos Therapeutics Inc. reported two key corporate governance changes. The board’s Audit Committee dismissed CBIZ CPAs P.C. as independent registered public accounting firm and approved the appointment of Grant Thornton LLP for the fiscal year ending December 31, 2026. The company states CBIZ’s prior audit reports for 2024 and 2025 contained no adverse opinions, disclaimers, or qualifications, and there were no disagreements or reportable events through May 18, 2026.
The company also detailed a Separation and Release Agreement with former Chief Financial Officer, Treasurer, and Secretary Francis Knuettel II, whose employment ended April 10, 2026. Under the agreement, he will receive earned but unpaid compensation, reimbursement of business expenses, separation pay equal to 12 months of base salary, or $430,000, and accelerated vesting of certain stock options and RSUs that would have vested in the 12 months after the separation date, subject to the agreement becoming effective after a seven‑day revocation period.